CureVac (NASDAQ:CVAC) Sets New 12-Month Low at $2.54

CureVac (NASDAQ:CVAC)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $2.54 and last traded at $2.62, with a volume of 157201 shares traded. The stock had previously closed at $2.65.

Wall Street Analyst Weigh In

Separately, Guggenheim reaffirmed a “neutral” rating on shares of CureVac in a research note on Friday, April 5th.

CureVac Stock Performance

The stock’s 50 day moving average is $3.24 and its 200 day moving average is $4.36. The company has a quick ratio of 3.41, a current ratio of 3.56 and a debt-to-equity ratio of 0.06.

Institutional Investors Weigh In On CureVac

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its stake in CureVac by 95.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock valued at $39,000 after acquiring an additional 2,804 shares during the last quarter. Optiver Holding B.V. lifted its holdings in shares of CureVac by 2,407.0% during the 3rd quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock worth $47,000 after acquiring an additional 6,571 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of CureVac during the 1st quarter worth about $59,000. Tower Research Capital LLC TRC lifted its holdings in shares of CureVac by 482.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,936 shares of the company’s stock worth $93,000 after acquiring an additional 7,402 shares during the period. Finally, JPMorgan Chase & Co. purchased a new position in shares of CureVac during the 2nd quarter worth about $104,000. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.